Wells A. Messersmith, MD, FACP
Professor of Medicine
Head, Division of Medical Oncology
Program Co-Leader, Developmental Therapeutics
University of Colorado Cancer Center
University of Colorado School of Medicine
Physicians: Maximum of 1.0 AMA PRA Category 1 CreditTM
Registered Nurses: 0.8 contact hours; Designated for 0.4 pharmacotherapy contact hours for APRN
Colorectal cancer is the third most common cancer in men and women. Current evidence-based guidelines recommend that all metastatic colorectal tumors be tested for RAS mutations (both KRAS and NRAS) and BRAF mutations, as the presence of such mutations has implications for treatment. Clinical practice is variable, however, and many patients do not receive guideline-based care. This activity will examine optimal management of metastatic colorectal cancer.
This activity is jointly provided by Postgraduate Institute for Medicine and MCM Education.
Medical oncologists, radiation oncologists, surgical oncologists, pathologists, oncology NPs and PAs, oncology nurses and other healthcare providers involved in the treatment of patients with colorectal cancer
Upon completion of this educational activity, the participant should be able to:
- Discuss the clinical relevance of extended RAS analysis at diagnosis and first relapse, BRAF testing, and MSI testing during workup for mCRC patients.
- Apply the most current evidence-based clinical practice guidelines to the management of patients with mCRC.
- Describe a multidisciplinary team approach to the management of mCRC involving surgery, radiation, and other treatment modalities.
- Review efficacy and safety data from clinical trials of approved agents being investigated for new indications in mCRC and for emerging investigational agents for the management of mCRC.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest
The faculty reported the following financial relationships or relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:
Dr. Messersmith, contracted research for Roche/Genentech, Pfizer, Takeda
The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose. The MCM Education planners and managers have nothing to disclose.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and MCM Education. Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.8 contact hours. Designated for 0.4 pharmacotherapy contact hours for Advance Practice Registered Nurses.
Commercial Support Statements
This activity is supported by an educational grant from Bayer Healthcare Pharmaceuticals, Inc.
The estimated time to complete this activity is 1.0 hour. Participants must 1)read the learning objectives and disclosures; 2)study the educational activity; and 3)complete the post-test and the evaluation form. Your post-test will automatically be graded. If you successfully complete the post-test (score of 80% or higher), your certificate will be made available immediately. You may retake the post-test until successful.
- Computer Requirements: Minimum System Requirements: • Pentium III, 600 MHz or Equivalent Processor • 512 MB of RAM • Windows XP, Vista, or 7 • Mac OS X • 800x600 Monitor Resolution • 16-bit Color • 16 bit Sound Card with Speakers
- Accessing Activity:
* Click "Start Program"
* Take the pre-test
* Review the activity
* Take the post-test and score 80%
* You are allowed a total of 3 attempts
* Complete the evaluation
* View, print, or save a certificate verifying your credit/participation in this activity
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.